Si desitges distingir els teus productes, serveis o tots dos dels d'una altra empresa, és possible que necessitis una marca o nom comercial. Descobreix què són, en què consisteix el seu procediment de registri i què implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tens un nou dispositiu, producte o procediment que resolgui un problema tècnic o tingui un avantatge pràctic, existeixen diferents formis de protegir-ho a Espanya i en altres països. Descobreix com fer-ho.
La teva innovació resideix en l'estètica, l'ornamentació o l'aparença del teu producte? Protegeix-la mitjançant un disseny industrial. Descobreix quins drets confereix el registri i com realitzar la tramitació.
Les indicacions geogràfiques protegeixen el nom d’un producte originari d’una zona geogràfica, a la qual li deu una determinada qualitat, reputació o una altra característica. Descobreix què són, en què consisteix el seu procediment de registre i quins beneficis atorguen.
Els patents publicades a tot el món són una valuosa font d'informació científica, tècnica i comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Si ets emprenedor/a o una empresa i vols potenciar i millorar la rendibilitat del teu negoci protegint de forma adequada els actius intangibles de la teva organització, en aquest espai trobaràs el necessari.
251
resultados
Última actualización
16/10/2026 [06:52:00]
Resultados 200 a 225 de 251
Resumen de: US20260294807A1
This disclosure relates to compositions and methods for treating vascular disorders, including, for example, arteriovenous fistula (AVF) failure, stenosis, restenosis, and atherosclerosis.
Resumen de: US20260295071A1
A micro/nanoparticle formed of self-assembling micro/nanoparticle forming components, wherein at least one self-assembling micro/nanoparticle forming component is a cationic micro/nanoparticle forming component and at least one is an alginate oligomer which has at least 70% mannuronate residues, and the micro/nanoparticle further includes a molecule of interest, optionally wherein the molecule of interest is covalently bound to one or more of the self-assembling micro/nanoparticle forming components. Also disclosed are methods for translocating a cationic micro/nanoparticle across a mucus layer including contacting the mucus layer with at least one alginate oligomer, the alginate oligomer having at least 70% mannuronate residues, together with the cationic micro/nanoparticle; or contacting the cationic micro/nanoparticle with an alginate oligomer having at least 70% mannuronate residues thereby forming a micro/nanoparticle carrying the alginate oligomer, and contacting the mucus layer with the micro/nanoparticle.
Resumen de: US20260295047A1
0000 The present application relates to activable inorganic nanoparticles which can be used in the health sector, in particular in human health, to disturb, alter or destroy target cancerous cells, tissues or organs. It more particularly relates to nanoparticles which can generate a surprisingly efficient therapeutic effect, when concentrated inside the tumor and exposed to ionizing radiations. The invention also relates to pharmaceutical compositions comprising a population of nanoparticles as defined previously, as well as to their uses.
Resumen de: US20260295048A1
0000 A magnetic hydrogel material with both bactericidal property and thermoresponsive contractility, a preparation method and an application thereof are provided. The magnetic hydrogel material adopts a poly(N-isopropylacrylamide) (PNIPAm) copolymerized polyacrylamide (PAm) double-network hydrogel as a matrix. Nano clay is grafted on the matrix to form a copolymer double-network hydrogel with thermoresponsive contractility, and a magnetic substance and tannic acid are doped in the copolymer double-network hydrogel to obtain the magnetic hydrogel material. The PNIPAm copolymerized PAm double-network hydrogel is formed through a radical polymerization reaction of N-isopropylacrylamide and acrylamide. The magnetic hydrogel material has both bactericidal property and mechanical loading property. The magnetic hydrogel material can effectively kill Staphylococcus aureus and Escherichia coli, and promote the healing of the infected diabetic wounds through bactericidal property and sustained mechanical loading on wounds.
Resumen de: WO2026206923A1
A protein-bound lipid nanoparticle, wherein an apparent pKa of the surface of the protein-bound lipid nanoparticle is 7.0 to 10.0, and the apparent pKa of the surface is measured by a TNS (p-toluidino-6-naphthalene sulfonic acid) measurement method. A method of manufacturing the protein-bound lipid nanoparticle, including: (a) mixing a first solution and a second solution to obtain a first mixed solution; (b) mixing the first mixed solution and a protein either simultaneously with step (a) or within an hour after completion of step (a) to obtain a second mixed solution; and (c) dialyzing, filtrating, or diluting the second mixed solution either simultaneously with step (b) or within an hour after completion of step (b), wherein the first solution includes ethanol and a lipid having a maleimide group in its molecule, the second solution includes a nucleic acid and a buffer, and the protein includes a thiol group.
Resumen de: WO2026206752A1
Provided are compositions comprising lipid nanoparticle formulations (LNPs) and methods of use thereof for treating cancer or enhancing antitumor immunity. The compositions comprise chemotherapeutic-derived ionizable lipids that induce immunogenic cell death in cancer cells and deliver mRNAs encoding FMS-like tyrosine kinase 3 ligand (Flt3L) and/or CD40 ligand (CD40L) to promote dendritic cell mobilization and activation. Methods of treating cancer using the compositions, optionally in combination with checkpoint inhibitors, are also provided.
Resumen de: US20260294832A1
0000 The disclosure relates to block copolymer nanoparticles for therapeutic delivery of nucleic acids, and methods therefor. More particularly, the invention relates to polymer nanoparticles, such as reversible addition-fragmentation chain transfer (RAFT) polymer compositions, for delivering RNAs.
Resumen de: WO2026201207A1
Provided herein are a lipid compound, a lipid nanoparticle composition, and use thereof. First provided herein is a compound represented by formula I or a pharmaceutically acceptable form thereof. The compound represented by formula I is a lipid compound, which can be used in combination with other lipid components (such as neutral lipids, cholesterol, and polymer-conjugated lipids) to form lipid nanoparticles for delivering a therapeutic agent (such as nucleic acid molecules) for therapeutic or prophylactic purposes. Further provided herein is a lipid nanoparticle composition comprising the lipid compound represented by formula I.
Resumen de: WO2026205143A1
The purpose of the present invention is to provide a PEG lipid that makes it possible to prepare an LNP with which the production amount of an anti-PEG antibody in vivo is suppressed. A PEG lipid for preparing lipid nanoparticles according to the present invention is represented by formula (I): R1-L1-R2. (In the formula, R1 represents a zwitterionic moiety having a positive charge and a negative charge; L1 represents a polyethylene glycol chain; and R2 represents a lipid moiety.)
Resumen de: WO2026206929A1
A pharmaceutical composition contains protein-bound nanoparticles and 5 mM to 500 mM of arginine. The pharmaceutical composition may further contain 10 mM to 2 M of a disaccharide. The pharmaceutical composition may be in the form of a lyophilized formulation. The protein-bound nanoparticles may contain cationic lipids or ionizable cationic lipids, phospholipids, sterols, polyethylene glycol (PEG)-modified lipids, and conjugates of proteins and lipids
Resumen de: WO2026207117A1
Compositions and methods are provided for glaucoma or ocular hypertension therapy. The compositions of the disclosure include solid drug nanoparticles comprised of at least two active agents: (i) a neuroprotectant, and (ii) a β adrenergic blocker. In some embodiments the neuroprotectant is maprotiline. In some embodiments the β adrenergic blocker is betaxolol. The combination of agents in nanoparticle form is shown to have synergistic benefits in the treatment of ocular disease.
Resumen de: US20260294825A1
0000 The present invention relates to a microfluidic platform for producing lipid nanoparticles (LNPs), which comprises a microfluidic channel for producing lipid nanoparticles inside using centrifugal force, at least one inlet configured to supply a fluid into the microfluidic channel, and at least one outlet configured to discharge the fluid from the microfluidic channel, the platform being provided in the form of a disk member.
Resumen de: WO2026202775A1
Compositions for delivering azelaic acid in a substantially molecularly dispersed, non- crystalline state are provided, comprising acetamide monoethanolamine (Acetamide MEA) as the primary solubilizing agent for azelaic acid and as crystallization inhibitor. The compositions may comprise azelaic acid at concentrations of up to about 25% by weight, exhibiting physical stability and optical clarity. The compositions are structured as submicron emulsions, gel compositions and topical formulations, optionally including structuring systems, and/or rheology modifiers, to further enhance stability and resistance to crystallization. Such compositions are useful for treatment of skin diseases, disorders, or conditions that may benefit from topical application of azelaic acid.
Resumen de: WO2026204819A1
Provided is a polyalkylene glycol lipid represented by formula (1). (R1 and R2 are each independently a hydrogen atom, an aliphatic hydrocarbon group having 15-22 carbon atoms or an acyl group having 15-22 carbon atoms. k, l and m are numbers that satisfy the relationships 6≥k≥0, 6≥l≥0, 6≥m≥0 and k+l+m≥2. A is an oxygen atom, an ester bond, a carbonate bond or a carbamate bond. B is a divalent hydrocarbon group having 1-4 carbon atoms, n is 21-226, C is a divalent hydrocarbon group having 1-4 carbon atoms, and D is an atomic group represented by formula (2a) or formula (2b) shown in the description.
Resumen de: US20260295072A1
The disclosure relates to block copolymer nanoparticles for in vivo screening and for in vivo therapeutic delivery, and methods therefor. More particularly, the invention relates to polymer nanoparticles, such as reversible addition-fragmentation chain transfer (RAFT) polymer compositions, for delivering circRNA.
Resumen de: WO2026202770A1
A niosomal formulation of bioactive component for topical application and a process of preparation thereof 0069 The invention discloses a niosomal formulation of bioactive components for topical application. The niosomal formulation comprises non-ionic surfactants, cholesterol, glycerol, water, bioactive component propylene glycol and polysachharides. The process of preparation of niosomal formulation comprises steps of mixing cholesterol and non-ionic surfactants, homogenizing the mixture, mixing the bioactive component, propylene glycol and glycerol, nano milling the mixture, nano milling the homogenized and nano milled mixture to obtain multilamellar niosomes, homogenization to obtain large unilamellar niosomes, homogenization to further obtain small unilamellar niosomes. The process involves optimized temperatures favoring the formation of stable niosomes. The niosomal formulation is topically administered and does not induce any skin irritation. The niosomal formulation is safe, bioavailable and highly stable.
Resumen de: WO2026199066A1
Provided are novel sulfur-containing lipids and nanoparticles containing such lipids and a cargo molecule, such as a nucleic acid, methods to formulate the lipids with nucleic acids to produce lipid nanoparticles and chemical routes for making the lipids. The lipids may have the structure of Formula A as defined herein (Formula A)
Resumen de: WO2026206644A1
A composition comprising a compound having the structure (I), (II), (III), or (IV) is provided: wherein: each R1 is independently selected from aliphatic alkyl C4-C100 groups optionally substituted with one or more of alkenyl, alkynyl, hydroxyl, amide, ester, and/or ether groups; R2 is selected from -OCH2CH2-p, -OCH2CH2-p-O-, or; R3 is selected from Formula (V), (VI), (VII), (VIII); R4 is an alkyl chain selected from -CH2-t; and m, p, s and t are independently selected from integers from 1 to 120. The compound is useful as a liver asialoglycoprotein receptor-targeted therapeutic agent in the form of a lipid nanoparticle, a liposome or a micelle including a drug or nucleic acid.
Resumen de: US20260295050A1
0000 Lipid nanoparticles described herein are useful in photodynamic therapy (PDT), a light-activated cancer treatment that uses photosensitizers (PSs) to generate reactive oxygen species (ROS), leading to tumor cell death. These lipid nanoparticles are capable of producing varying levels of oxygen-based radicals and singlet oxygen. In preferred embodiments, the lipid nanoparticles are verteporfin-lipid nanoparticles. Fine-tuning design features of the lipid nanoparticles, such as Type I ROS generation and predominantly ER and mitochondrial localization, provides a more robust induction of immunogenic cell death (ICD).
Resumen de: WO2026202325A1
The present invention pertains to ionizable lipids and their compositions, as well as methods and processes of their preparation and uses thereof. More specifically, the present invention relates to novel ionizable phospholipid compounds or pharmaceutically acceptable salts, tautomers, or stereoisomers thereof. The present invention further relates to lipid nanoparticle compositions comprising said ionizable phospholipid compounds.
Resumen de: AU2025201666A1
Title of the invention: New composition and method for green manufacture of robust, stable and monodisperse drug carriers using the improved Mozafari method at ambient temperature Inventors: Elham TAGHAVI; Marcel Reza MOZAFARI; Nasim REIHANI; Ali AL-SAMYDAI The embodiments herein provide a new formulation and method for robust manufacturing of various stable micro- and nano-carrier systems for the encapsulation of bioactive agents, pharmaceuticals, minerals and other compounds. According to one embodiment herein, a fine- tuned composition of pharmaceutical ingredients, excipients, solvents, co-solvents, antioxidants, lipids, helper-lipids, sterols and alike, along with one or more active compound(s) is introduced. The combination of the mentioned ingredients is selected such that the combined phase transition temperature of the carrier system is substantially below room temperature. According to another embodiment presented here an easily scalable method is introduced for producing a microcarrier or nanocarrier complex of a pharmaceutical or biological or food or other molecules and compounds disposed within a micro- or nano-carrier system. Whereas the currently available green-procedure for large-scale manufacture of carrier complexes / encapsulation systems known as Mozafari method has the limitation of using moderately high temperatures, the improved Mozafari method can be practiced at any room temperature (even below 20°C). The method, hence, can be applied to all known
Resumen de: US20260294830A1
Among other things, in general, polymer-lipid nanoparticles (PLNPs) are disclosed that have charge switching properties which allow for efficient release of payloads in the pH environment of the endosome. PLNPs and methods of manufacture thereof are disclosed for charge switchable PLNPs having an anionic polymeric shell surrounding ionizable cationic lipids (also potentially including helper lipids and cholesterol) that are in complex with a cargo (such as, in a non-limiting example, therapeutically useful nucleic acids).
Resumen de: US20260294829A1
0000 The present disclosure relates to a nucleic acid-lipid nanoparticle composition and a lyophilized preparation thereof, and further relates to a preparation method for the composition and a use of the composition. The nucleic acid-lipid nanoparticle composition of the present disclosure comprises lactate, so that the stability of nucleic acid-lipid nanoparticles is improved in a lyophilization process and a prepared lyophilized preparation. According to the present disclosure, the total time of a freeze-drying process for the nucleic acid-lipid nanoparticles can be shortened, and energy consumption and the time cost of product scale-up production can be greatly reduced; the rehydration of lyophilized nucleic acid-lipid nanoparticles is quick, and the total amount of nucleic acids, the encapsulation efficiency, and the nucleic acid integrity are high; in addition, a lyophilized and rehydrated preparation has cell transfection efficiency not significantly different from that of a non-lyophilized nucleic acid-lipid nanoparticle stock solution, and has a high in vivo immune response, even exceeding that of the non-lyophilized nucleic acid-lipid nanoparticle stock solution.
Resumen de: US20260295035A1
Provided herein are fragments of the gE protein of varicella-zoster virus and therapeutic nucleic acid molecules for managing, preventing and/or treating a disease or disorder caused by varicella-zoster virus or by infection therewith. Also provided herein are therapeutic compositions, including vaccines and lipid nanoparticles, comprising the therapeutic nucleic acids and related therapeutic methods and uses.
Nº publicación: WO2026207228A2 01/10/2026
Solicitante:
NAVA THERAPEUTICS INC [US]
NAVA THERAPEUTICS, INC.
Resumen de: WO2026207228A2
This disclosure relates to novel lipid compounds containing a head group containing an aromatic or heteroaromatic group and a monoamine, a linker group, and a tertiary amine branched tail group, wherein the chain length counting the total number of atoms forming the chain connecting the head group and the tail group is no more than nine (e.g., is nine). The disclosure also provides a lipid composition comprising these novel lipid compounds and pharmaceutical compositions comprising these lipid compositions. The disclosure additionally provides methods for delivering a therapeutic agent to a cell or a subject and methods of treating a disease or disorder (e.g., a kidney disease or disorder) in a subject employing the lipid composition or pharmaceutical compositions comprising these novel lipid compounds and the therapeutic agent.
BOPI
Sede Electrónica
